Risk	O
and	O
Predictors	O
of	O
Variceal	B:C0333106
Bleeding	I:C0333106
in	O
Cirrhosis	O
Patients	O
Receiving	O
Primary	O
Prophylaxis	I:C0033107
With	O
Non-Selective	O
Beta-Blockers	O
.	O

Risk	O
and	O
Predictors	O
of	O
Variceal	O
Bleeding	I:C0333106
in	O
Cirrhosis	B:C1623038
Patients	O
Receiving	O
Primary	O
Prophylaxis	I:C0033107
With	O
Non-Selective	O
Beta-Blockers	O
.	O

Risk	O
and	O
Predictors	O
of	O
Variceal	O
Bleeding	I:C0333106
in	O
Cirrhosis	O
Patients	O
Receiving	O
Primary	B:C0033107
Prophylaxis	I:C0033107
With	O
Non-Selective	O
Beta-Blockers	O
.	O

Prior	O
studies	O
have	O
demonstrated	O
the	O
efficacy	O
of	O
non-selective	O
beta	O
-	O
blockers	O
(	O
NSBB	O
)	O
in	O
preventing	O
first	O
variceal	B:C0333106
bleeding	I:C0333106
in	O
patients	O
with	O
cirrhosis	O
.	O

Prior	O
studies	O
have	O
demonstrated	O
the	O
efficacy	O
of	O
non-selective	O
beta	O
-	O
blockers	O
(	O
NSBB	O
)	O
in	O
preventing	O
first	O
variceal	O
bleeding	I:C0333106
in	O
patients	O
with	O
cirrhosis	B:C1623038
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
overall	O
effectiveness	O
of	O
NSBB	O
in	O
routine	O
clinical	B:C0086388
care	I:C0086388
.	O

We	O
conducted	O
a	O
retrospective	B:C2985505
cohort	I:C2985505
study	I:C2985505
of	O
cirrhotic	O
patients	O
without	O
prior	O
bleeding	O
who	O
initiated	O
a	O
NSBB	O
(	O
propranolol	O
,	O
nadolol	O
)	O
at	O
any	O
Veterans	O
Administration	I:C0020030
facility	I:C0020030
between	O
2008	O
and	O
2013	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
of	O
cirrhotic	B:C1623038
patients	O
without	O
prior	O
bleeding	O
who	O
initiated	O
a	O
NSBB	O
(	O
propranolol	O
,	O
nadolol	O
)	O
at	O
any	O
Veterans	O
Administration	I:C0020030
facility	I:C0020030
between	O
2008	O
and	O
2013	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
of	O
cirrhotic	O
patients	O
without	O
prior	O
bleeding	B:C0019080
who	O
initiated	O
a	O
NSBB	O
(	O
propranolol	O
,	O
nadolol	O
)	O
at	O
any	O
Veterans	O
Administration	I:C0020030
facility	I:C0020030
between	O
2008	O
and	O
2013	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
of	O
cirrhotic	O
patients	O
without	O
prior	O
bleeding	O
who	O
initiated	O
a	O
NSBB	O
(	O
propranolol	B:C0033497
,	O
nadolol	O
)	O
at	O
any	O
Veterans	O
Administration	I:C0020030
facility	I:C0020030
between	O
2008	O
and	O
2013	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
of	O
cirrhotic	O
patients	O
without	O
prior	O
bleeding	O
who	O
initiated	O
a	O
NSBB	O
(	O
propranolol	O
,	O
nadolol	B:C0027302
)	O
at	O
any	O
Veterans	O
Administration	I:C0020030
facility	I:C0020030
between	O
2008	O
and	O
2013	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
of	O
cirrhotic	O
patients	O
without	O
prior	O
bleeding	O
who	O
initiated	O
a	O
NSBB	O
(	O
propranolol	O
,	O
nadolol	O
)	O
at	O
any	O
Veterans	B:C0020030
Administration	I:C0020030
facility	I:C0020030
between	O
2008	O
and	O
2013	O
.	O

The	O
primary	O
outcome	O
was	O
variceal	B:C0333106
bleeding	I:C0333106
within	O
12	O
months	O
.	O

We	O
conducted	O
Cox-proportional	B:C0033489
hazards	I:C0033489
analyses	I:C0033489
to	O
identify	O
demographic	O
,	O
clinical	O
,	O
and	O
NSBB	O
-	O
related	O
(	O
type	O
of	O
NSBB	O
,	O
mean	O
dose	O
,	O
dose	O
change	I:C0554834
,	O
and	O
heart	O
rate	I:C1997754
response	I:C1997754
)	O
factors	O
associated	O
with	O
variceal	O
bleeding	I:C0333106
.	O

We	O
conducted	O
Cox-proportional	O
hazards	I:C0033489
analyses	I:C0033489
to	O
identify	O
demographic	O
,	O
clinical	O
,	O
and	O
NSBB	O
-	O
related	O
(	O
type	O
of	O
NSBB	O
,	O
mean	O
dose	O
,	O
dose	B:C0554834
change	I:C0554834
,	O
and	O
heart	O
rate	I:C1997754
response	I:C1997754
)	O
factors	O
associated	O
with	O
variceal	O
bleeding	I:C0333106
.	O

We	O
conducted	O
Cox-proportional	O
hazards	I:C0033489
analyses	I:C0033489
to	O
identify	O
demographic	O
,	O
clinical	O
,	O
and	O
NSBB	O
-	O
related	O
(	O
type	O
of	O
NSBB	O
,	O
mean	O
dose	O
,	O
dose	O
change	I:C0554834
,	O
and	O
heart	B:C1997754
rate	I:C1997754
response	I:C1997754
)	O
factors	O
associated	O
with	O
variceal	O
bleeding	I:C0333106
.	O

We	O
conducted	O
Cox-proportional	O
hazards	I:C0033489
analyses	I:C0033489
to	O
identify	O
demographic	O
,	O
clinical	O
,	O
and	O
NSBB	O
-	O
related	O
(	O
type	O
of	O
NSBB	O
,	O
mean	O
dose	O
,	O
dose	O
change	I:C0554834
,	O
and	O
heart	O
rate	I:C1997754
response	I:C1997754
)	O
factors	O
associated	O
with	O
variceal	B:C0333106
bleeding	I:C0333106
.	O

Of	O
5,775	O
patients	O
,	O
678	O
(	O
11.7	O
%	O
)	O
developed	O
variceal	B:C0333106
bleeding	I:C0333106
.	O

Mean	O
daily	O
dose	O
of	O
NSBB	O
was	O
<	O
40	O
mg	O
in	O
58.8	O
%	O
,	O
18.1	O
%	O
had	O
either	O
upward	B:C1282911
or	O
downward	O
titration	O
in	O
NSBB	O
dose	O
,	O
and	O
9.8	O
%	O
had	O
hemodynamic	O
response	I:C0019010
.	O

Mean	O
daily	O
dose	O
of	O
NSBB	O
was	O
<	O
40	O
mg	O
in	O
58.8	O
%	O
,	O
18.1	O
%	O
had	O
either	O
upward	O
or	O
downward	B:C0205104
titration	O
in	O
NSBB	O
dose	O
,	O
and	O
9.8	O
%	O
had	O
hemodynamic	O
response	I:C0019010
.	O

Mean	O
daily	O
dose	O
of	O
NSBB	O
was	O
<	O
40	O
mg	O
in	O
58.8	O
%	O
,	O
18.1	O
%	O
had	O
either	O
upward	O
or	O
downward	O
titration	B:C0162621
in	O
NSBB	O
dose	O
,	O
and	O
9.8	O
%	O
had	O
hemodynamic	O
response	I:C0019010
.	O

Mean	O
daily	O
dose	O
of	O
NSBB	O
was	O
<	O
40	O
mg	O
in	O
58.8	O
%	O
,	O
18.1	O
%	O
had	O
either	O
upward	O
or	O
downward	O
titration	O
in	O
NSBB	O
dose	O
,	O
and	O
9.8	O
%	O
had	O
hemodynamic	B:C0019010
response	I:C0019010
.	O

Patients	O
who	O
were	O
younger	O
,	O
with	O
ascites	B:C0003962
,	O
greater	O
medical	O
comorbidity	O
,	O
and	O
higher	O
Model	O
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
(	O
Model	O
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
)	O
scores	O
had	O
a	O
higher	O
risk	O
of	O
variceal	O
bleeding	I:C0333106
.	O

Patients	O
who	O
were	O
younger	O
,	O
with	O
ascites	O
,	O
greater	O
medical	O
comorbidity	O
,	O
and	O
higher	O
Model	B:C3826979
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
(	O
Model	O
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
)	O
scores	O
had	O
a	O
higher	O
risk	O
of	O
variceal	O
bleeding	I:C0333106
.	O

Patients	O
who	O
were	O
younger	O
,	O
with	O
ascites	O
,	O
greater	O
medical	O
comorbidity	O
,	O
and	O
higher	O
Model	O
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
(	O
Model	B:C3826979
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
)	O
scores	O
had	O
a	O
higher	O
risk	O
of	O
variceal	O
bleeding	I:C0333106
.	O

Patients	O
who	O
were	O
younger	O
,	O
with	O
ascites	O
,	O
greater	O
medical	O
comorbidity	O
,	O
and	O
higher	O
Model	O
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
(	O
Model	O
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
)	O
scores	B:C1718072
had	O
a	O
higher	O
risk	O
of	O
variceal	O
bleeding	I:C0333106
.	O

Patients	O
who	O
were	O
younger	O
,	O
with	O
ascites	O
,	O
greater	O
medical	O
comorbidity	O
,	O
and	O
higher	O
Model	O
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
(	O
Model	O
for	I:C3826979
end	I:C3826979
-	I:C3826979
stage	I:C3826979
liver	I:C3826979
disease	I:C3826979
)	O
scores	O
had	O
a	O
higher	O
risk	O
of	O
variceal	B:C0333106
bleeding	I:C0333106
.	O

Patients	O
on	O
a	O
higher	O
daily	O
dose	O
(	O
>	O
60	O
vs.	O
<	O
40	O
mg	O
,	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.64	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.51	O
-	O
0.81	O
)	O
,	O
who	O
had	O
either	O
upward	B:C1282911
or	O
downward	O
dose	O
titration	O
(	O
adjusted	O
HR	O
0.69	O
;	O
95	O
%	O
CI	O
:	O
0.52-0.90	O
and	O
0.64	O
;	O
95	O
%	O
CI	O
0.45-0.90	O
,	O
respectively	O
)	O
,	O
and	O
those	O
who	O
achieved	O
hemodynamic	O
response	I:C0019010
(	O
adjusted	O
HR	O
0.75	O
;	O
95	O
%	O
CI	O
=	O
0.57	O
-	O
1.0	O
)	O
had	O
lower	O
risk	O
.	O

Patients	O
on	O
a	O
higher	O
daily	O
dose	O
(	O
>	O
60	O
vs.	O
<	O
40	O
mg	O
,	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.64	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.51	O
-	O
0.81	O
)	O
,	O
who	O
had	O
either	O
upward	O
or	O
downward	B:C0205104
dose	O
titration	O
(	O
adjusted	O
HR	O
0.69	O
;	O
95	O
%	O
CI	O
:	O
0.52-0.90	O
and	O
0.64	O
;	O
95	O
%	O
CI	O
0.45-0.90	O
,	O
respectively	O
)	O
,	O
and	O
those	O
who	O
achieved	O
hemodynamic	O
response	I:C0019010
(	O
adjusted	O
HR	O
0.75	O
;	O
95	O
%	O
CI	O
=	O
0.57	O
-	O
1.0	O
)	O
had	O
lower	O
risk	O
.	O

Patients	O
on	O
a	O
higher	O
daily	O
dose	O
(	O
>	O
60	O
vs.	O
<	O
40	O
mg	O
,	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.64	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.51	O
-	O
0.81	O
)	O
,	O
who	O
had	O
either	O
upward	O
or	O
downward	O
dose	O
titration	B:C0162621
(	O
adjusted	O
HR	O
0.69	O
;	O
95	O
%	O
CI	O
:	O
0.52-0.90	O
and	O
0.64	O
;	O
95	O
%	O
CI	O
0.45-0.90	O
,	O
respectively	O
)	O
,	O
and	O
those	O
who	O
achieved	O
hemodynamic	O
response	I:C0019010
(	O
adjusted	O
HR	O
0.75	O
;	O
95	O
%	O
CI	O
=	O
0.57	O
-	O
1.0	O
)	O
had	O
lower	O
risk	O
.	O

Patients	O
on	O
a	O
higher	O
daily	O
dose	O
(	O
>	O
60	O
vs.	O
<	O
40	O
mg	O
,	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.64	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.51	O
-	O
0.81	O
)	O
,	O
who	O
had	O
either	O
upward	O
or	O
downward	O
dose	O
titration	O
(	O
adjusted	O
HR	O
0.69	O
;	O
95	O
%	O
CI	O
:	O
0.52-0.90	O
and	O
0.64	O
;	O
95	O
%	O
CI	O
0.45-0.90	O
,	O
respectively	O
)	O
,	O
and	O
those	O
who	O
achieved	O
hemodynamic	B:C0019010
response	I:C0019010
(	O
adjusted	O
HR	O
0.75	O
;	O
95	O
%	O
CI	O
=	O
0.57	O
-	O
1.0	O
)	O
had	O
lower	O
risk	O
.	O

Approximately	O
12	O
%	O
of	O
patients	O
bled	B:C0019080
while	O
being	O
on	O
NSBB	O
for	O
primary	O
prophylaxis	I:C0033107
.	O

Approximately	O
12	O
%	O
of	O
patients	O
bled	O
while	O
being	O
on	O
NSBB	O
for	O
primary	B:C0033107
prophylaxis	I:C0033107
.	O

A	O
higher	O
NSBB	O
dose	O
and	O
dose	O
titration	B:C0162621
were	O
protective	O
;	O
yet	O
most	O
patients	O
did	O
not	O
have	O
the	O
NSBB	O
dose	O
titrated	O
to	O
the	O
recommended	O
levels	O
.	O

A	O
higher	O
NSBB	O
dose	O
and	O
dose	O
titration	O
were	O
protective	O
;	O
yet	O
most	O
patients	O
did	O
not	O
have	O
the	O
NSBB	O
dose	O
titrated	B:C0162621
to	O
the	O
recommended	O
levels	O
.	O

Our	O
data	O
highlight	O
the	O
need	O
for	O
careful	O
monitoring	B:C1283169
of	O
cirrhotic	O
patients	O
on	O
NSBB	O
.	O

Our	O
data	O
highlight	O
the	O
need	O
for	O
careful	O
monitoring	O
of	O
cirrhotic	B:C1623038
patients	O
on	O
NSBB	O
.	O

